Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 02 2024 - 9:05AM
Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company
developing gene therapies to address common diseases affecting
millions of people around the world, today announced three
presentations at the Association for Research in Vision and
Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9,
2024 in Seattle, WA.
Kriya’s pipeline includes gene therapies across several
therapeutic areas including ophthalmology, metabolic disease and
neurology. KRIYA-825 is an adeno-associated virus (AAV) gene
therapy being developed for the treatment of Geographic Atrophy, a
prevalent degenerative retinal disease that is one of the leading
causes of blindness among elderly patients in the world.
"We are pleased to present three abstracts that demonstrate
progress in our efforts to advance our gene therapy product
candidate for the treatment of Geographic Atrophy, a gene therapy
that expresses a CR2-CR1 fusion protein. This fusion protein is
designed to inhibit the activity of C3 and C5 within the complement
cascade, which are validated therapeutic targets based on FDA
approved medicines for Geographic Atrophy," said Michele Stone,
Ph.D., Kriya's Chief Scientific Officer. "We are particularly
excited about the results from our biodistribution study in
non-human primates that used a novel delivery device to administer
AAV vector to the suprachoroidal space. The results demonstrate the
potential of this route of administration to enhance the efficiency
of protein expression in the affected cell layers of the retina
while minimizing intraocular inflammation in patients with
Geographic Atrophy."
The three abstracts are as follows:
Title: Evaluation of AAV2 Biodistribution after
Suprachoroidal Injection in NHPs Using a Novel Suprachoroidal
Delivery Device SystemSession: Gene and cell
therapies and other novel therapeutics Date: May
8, 2024 from 2:15 PM to 4:00 PM PDT
The authors demonstrate the ability of a novel device to deliver
an AAV vector to the suprachoroidal space in non-human primates and
achieve successful transduction of multiple layers of the retina.
Broad coverage was achieved from the injection site to the
posterior pole, including the macula and retina.
Title: Investigating the Efficacy of AAV
Mediated Expression of CR2-CR1 Fusion Protein, a Complement
Inhibitor, in Ameliorating Retinal Degeneration in
MiceSession: AMD: Translational
studiesDate: May 7, 2024 from 1:15 PM to 3:00 PM
PDT
The authors evaluate AAV mediated expression of a novel
complement receptor 2-complement receptor 1 (CR2-CR1) fusion
protein designed to inhibit the activity of complement components
C3 and C5 in a model of sodium iodate (NaIO3)-induced retinal
degeneration. The study demonstrates, in a dose dependent manner,
the potential of AAV.CR2-CR1 to preserve the
photoreceptor-containing outer nuclear layer (ONL).
Title: Measurement of a Complement Inhibitory
Protein Following AAV.CR2-CR1 Administration in a Retinal
Degradation Model of Geographic Atrophy
(GA)Session: AMD new drugs, delivery systems and
mechanism of actionDate: May 6, 2024 from 8:30 AM
to 10:15 AM PDT
The authors describe the development of an immunoassay designed
to quantify the expressed CR2-CR1 fusion protein and resultant
reduction in complement fragment accumulation following AAV.CR2-CR1
administration. This assay supports definitive pharmacology
studies, toxicology studies and future clinical trials.
About Kriya’s Geographic Atrophy Gene Therapy
ProgramKriya is developing KRIYA-825, a potential one-time
gene therapy for Geographic Atrophy that expresses a fusion
protein designed to inhibit the activity of complement C3 and C5,
with the objective of slowing Geographic Atrophy lesion growth and
vision loss. KRIYA-825 is designed to be administered through a
one-time in-office suprachoroidal injection.
GA affects approximately two million people in the United States
and the European Union. Existing treatments require monthly or
bimonthly physician-administered intravitreal injections that can
be burdensome for patients.
KRIYA-825 was designed with the following potential goals in
mind:
- Robust complement inhibition: A novel complement receptor
2-complement receptor 1 (CR2-CR1) fusion protein—where the CR1
domain is designed to block the activity of both complement C3 and
C5, while the CR2 domain is designed to bind to the surfaces of
cells where complement fragments deposit and cause damage;
- Multi-year durability: AAV mediated continuous expression of
CR2-CR1 fusion protein following a one-time injection to eliminate
the need for frequent intravitreal injections as required by
currently available therapies for GA; and
- Targeted delivery: One-time suprachoroidal injection to achieve
transduction of, and delivery of therapeutic protein to, retinal
cells while minimizing inflammation and overall patient
burden.
KRIYA-825 has not been approved for use by the U.S. Food and
Drug Administration. The clinical safety and efficacy of KRIYA-825
for the treatment of Geographic Atrophy has not yet been
established.
About Kriya TherapeuticsOur mission is to
revolutionize medicine, with the ultimate goal of eliminating human
suffering and enabling people to live without the burden of
disease. Kriya is a biopharmaceutical company developing gene
therapies to address common diseases affecting millions of people
around the world. With operations in Palo Alto, California and
Research Triangle Park, North Carolina, Kriya has raised over $600
million, which will be used to advance a broad pipeline of gene
therapies for ophthalmology, metabolic disease and neurology. For
more information, please visit www.kriyatx.com and follow us on
LinkedIn and X (Formerly Twitter).
Kriya Media Contact:
Kelli Perkins
kelli@redhousecomms.com